Pimavanserin, a novel antipsychotic for management of Parkinson’s disease psychosis

References

• Abrantes AM, Friedman JH, Brown RA, et al. Physical activity and neuropsychiatric symptoms of Parkinson disease. J Geriatr Psychiatry Neurol. 2012;25(3):138–145. PubMed PMID: 22914597.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386. PubMed PMID: 17082464.
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Move Disord. 2009;24(11):1641–1649. PubMed PMID: 19514014.
   PubMed Web of Science ®Google Scholar
• Santos-Garcia D, de la Fuente-Fernandez R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson’s disease. J Neurol Sci. 2013;332(1–2): 136–140. PubMed PMID: 23890935.
   PubMed Web of Science ®Google Scholar
• Fenelon G. Psychosis in Parkinson’s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr. 2008;13(3 Suppl 4): 18–25. PubMed PMID: 18323763.
   PubMed Web of Science ®Google Scholar
• Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001. PubMed PMID: 20697051.
   PubMedGoogle Scholar
• Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology. 2003;60(11):1756–1761. PubMed PMID: 12796526.
   PubMed Web of Science ®Google Scholar
• Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology. 2010;75(14):1270–1276.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48(8):938–942.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(6):629–634. PubMed PMID: 25892660.
   PubMed Web of Science ®Google Scholar
• Schrag A, Hovris A, Morley D, et al. Caregiver-burden in parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006;12(1): 35–41. PubMed PMID: 16271496.
   PubMed Web of Science ®Google Scholar
• Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Move Disord. 2007;22(8):1061–1068. PubMed PMID: 17266092.
   PubMed Web of Science ®Google Scholar
• Poewe W. Psychosis in Parkinson’s disease. Move Disord. 2003;18(Suppl 6): S80–7. PubMed PMID: 14502660.
   PubMed Web of Science ®Google Scholar
• Biglan KM, Holloway RG Jr., McDermott MP, et al., Parkinson Study Group C-PDI. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007;69(2):187–195. PubMed PMID: 17620552.
   PubMed Web of Science ®Google Scholar
• Ecker D, Unrath A, Kassubek J, et al. Dopamine agonists and their risk to induce psychotic episodes in Parkinson’s disease: a case-control study. BMC Neurol. 2009;9: 23. PubMed PMID: 19515253; PubMed Central PMCID: PMC2704166.
   PubMed Web of Science ®Google Scholar
• Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm. 2004;111(10–11): 1447–1453. PubMed PMID: 15480845.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Foltynie T, Lewis SJ, et al. Cognitive deficits and psychosis in Parkinson’s disease: a review of pathophysiology and therapeutic options. CNS Drugs. 2006;20(6): 477–505. PubMed PMID: 16734499.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Taylor JP, Weintraub D. Psychiatric issues in cognitive impairment. Move Disord. 2014;29(5): 651–662. PubMed PMID: 24757113; PubMed Central PMCID: PMC4380016.
   PubMed Web of Science ®Google Scholar
• Kitayama M, Wada-Isoe K, Nakaso K, et al. Clinical evaluation of Parkinson’s disease dementia: association with aging and visual hallucination. Acta Neurol Scand. 2007;116(3): 190–195. PubMed PMID: 17714333.
   PubMed Web of Science ®Google Scholar
• Zhu K, Van Hilten JJ, Putter H, et al. Risk factors for hallucinations in Parkinson’s disease: results from a large prospective cohort study. Move Disord. 2013;28(6): 755–762. PubMed PMID: 23520046.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Larsen JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16(5): 528–536. PubMed PMID: 11376470.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80(8):928–930. PubMed PMID: 19608786.
   PubMed Web of Science ®Google Scholar
• Mosimann UP, Mather G, Wesnes KA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2004;63(11): 2091–2096. PubMed PMID: 15596755.
   PubMed Web of Science ®Google Scholar
• Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging. 2008;25(8): 665–682. PubMed PMID: 18665659; PubMed Central PMCID: PMC3045853.
   PubMed Web of Science ®Google Scholar
• Chang A, Fox SH. Psychosis in Parkinson’s disease: epidemiology, pathophysiology, and management. Drugs. 2016;76(11):1093–1118. PubMed PMID: 27312429.
   PubMed Web of Science ®Google Scholar
• Lenka A, Jhunjhunwala KR, Saini J, et al. Structural and functional neuroimaging in patients with Parkinson’s disease and visual hallucinations: a critical review. Parkinsonism Relat Disord. 2015;21(7): 683–691. PubMed PMID: 25920541.
   PubMed Web of Science ®Google Scholar
• Barone P. Neurotransmission in Parkinson’s disease: beyond dopamine. Eur J Neurol. 2010;17(3): 364–376. PubMed PMID: 20050885.
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Birkmayer JD. Dopamine action and disorders of neurotransmitter balance. Gerontology. 1987;33(3–4): 168–171. PubMed PMID: 3653699.
   PubMed Web of Science ®Google Scholar
• Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson’s disease: on movement, mood, and madness. Move Disord. 2009;24(9): 1255–1266. PubMed PMID: 19412960.
   PubMed Web of Science ®Google Scholar
• Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin Pharmacother. 2011;12(13): 2009–2024. PubMed PMID: 21635198; PubMed Central PMCID: PMC3152685.
   PubMed Web of Science ®Google Scholar
• Joutsa J, Johansson J, Seppanen M, et al. Dorsal-to-ventral shift in midbrain dopaminergic projections and increased thalamic/raphe serotonergic function in early Parkinson disease. J Nucl Med. 2015;56(7): 1036–1041. PubMed PMID: 25952735.
   PubMed Web of Science ®Google Scholar
• Huot P, Johnston TH, Darr T, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Move Disord. 2010;25(10):1399–1408. PubMed PMID: 20629135.
   PubMed Web of Science ®Google Scholar
• Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010;67(4):416–421. PubMed PMID: 20385906.
   PubMed Web of Science ®Google Scholar
• Weiner DM, Burstein ES, Nash N, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 2001;299(1):268–276. PubMed PMID: 11561089.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72(21 Suppl 4): S1–136. PubMed PMID: 19470958.
   PubMed Web of Science ®Google Scholar
• Wand AP, Peisah C. Managing psychosis in Parkinson’s disease without drugs. Neurodegener Dis Manag. 2015;5(4): 271–274. PubMed PMID: 26295719.
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group.Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340(10):757–763. PubMed PMID: 10072410.
   PubMed Web of Science ®Google Scholar
• The French Clozapine Parkinson Study Group.Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet. 1999;353(9169):2041–2042. PubMed PMID: 10376627.
   PubMed Web of Science ®Google Scholar
• Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2000;12(3): 364–369. PubMed PMID: 10956570.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004;27(1): 4–5. PubMed PMID: 15090928.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55(6): 789–794. PubMed PMID: 10993997.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Move Disord. 2005;20(8): 958–963. PubMed PMID: 15800937.
   PubMed Web of Science ®Google Scholar
• Pintor L, Valldeoriola F, Bailles E, et al. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012;35(2): 61–66. PubMed PMID: 22388466.
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Move Disord. 2007;22(3): 313–318. PubMed PMID: 17034006.
   PubMed Web of Science ®Google Scholar
• Shotbolt P, M S, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat. 2009;5: 327–332. PubMed PMID: 19557142; PubMed Central PMCID: PMC2699657.
   PubMed Web of Science ®Google Scholar
• Hacksell U, Burstein ES, McFarland K, et al. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis. Neurochem Res. 2014;39(10):2008–2017. PubMed PMID: 24682754; PubMed Central PMCID: PMC4172996.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectr. 2016;21(4): 271–275. PubMed PMID: 27503570.
   PubMed Web of Science ®Google Scholar
• Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-(4-(2-methylpropyloxy)phen ylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006;317(2):910–918. PubMed PMID: 16469866.
   PubMed Web of Science ®Google Scholar
• Nordstrom AL, Mansson M, Jovanovic H, et al. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. Int J Neuropsychopharmacol. 2008;11(2):163–171. PubMed PMID: 17708779.
   PubMed Web of Science ®Google Scholar
• Divac N, Stojanovic R, Savic Vujovic K, et al. The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with Parkinson’s disease. Behav Neurol. 2016;2016: 4938154. PubMed PMID: 27504054; PubMed Central PMCID: PMC4967673.
   PubMed Web of Science ®Google Scholar
• Vanover KE, Robbins-Weilert D, Wilbraham DG, et al. Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. J Clin Pharmacol. 2007;47(6):704–714. PubMed PMID: 17473118.
   PubMed Web of Science ®Google Scholar
• Vanover KE, Robbins-Weilert D, Wilbraham DG, et al. The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers. J Clin Pharmacol. 2007;47(7):915–919. PubMed PMID: 17495279.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson’s disease psychosis. Am Coll Neuropsychopharmacol. 2010;35(4):881–892. PubMed PMID: 19907417; PubMed Central PMCID: PMC3055369.
   PubMed Web of Science ®Google Scholar
• Friedman J, Ravina B, Mills R. A multicenter, placebo controlled, double blind trail to examine the safety and efficacy of pimavanserin in the treatmenet of psychosis in Parkinson’s disease. Neurology. 2010;74(Suppl. 2):A299.
   Google Scholar
• Friedman JH. Pimavanserin for the treatment of Parkinson’s disease psychosis. Expert Opin Pharmacother. 2013;14(14): 1969–1975. PubMed PMID: 24016069.
   PubMed Web of Science ®Google Scholar
• Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540. PubMed PMID: 24183563.
   PubMed Web of Science ®Google Scholar
• Voss T, Bahr D, Cummings J, et al. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2013;19(3): 295–299. PubMed PMID: 23211417.
   PubMed Web of Science ®Google Scholar
• Hermanowicz S, Hermanowicz N. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson’s disease. Expert Rev Neurother. 2016;16(6): 625–633. PubMed PMID: 26908168.
   PubMed Web of Science ®Google Scholar
• Yasue I, Matsunaga S, Kishi T, et al. Serotonin 2A receptor inverse agonist as a treatment for Parkinson’s disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators. J Alzheimer’s Dis. 2016;50(3):733–740. PubMed PMID: 26757194.
   PubMed Web of Science ®Google Scholar
• Ballard C, Isaacson S, Mills R, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J Am Med Dir Assoc. 2015;16(10):898 e1–7. PubMed PMID: 26239690.
   Web of Science ®Google Scholar
• Isaacson S, Azulay JP, Ferreira J, et al. Long-term effectiveness of pimavanserin in PD psychosis: data from 2 open-label studies [abstract]. Move Disord. 2015;30(Suppl 1):149.
   Google Scholar
• INC. AP. 2016. Prescribing information for Nuplazid TM (pimavanserin) tablets, for oral use. http://www.acadia-pahrm.com/wp-content/uploads/2016/04/NUPLAZIDpimavanserin-Pachage-Insert.pdf
   Google Scholar
• Chendo I, Ferreira JJ. Pimavanserin for the treatment of Parkinson’s disease psychosis. Expert Opin Pharmacother. 2016;17(15): 2115–2124. PubMed PMID: 27609312.
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Vanover KE, Weiner DM, et al. Pimavanserin tartrate, a 5HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in health adult volunteers. Sleep Med. 2011;12(2):134–141. PubMed PMID: 21256805.
   PubMed Web of Science ®Google Scholar